A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Sep 17, 2026 - P1/2 | N=30 | Active, not recruiting | Sponsor: St. Petersburg State Pavlov Medical University | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2024 ➔ Sep 2026 | Trial primary completion date: Oct 2023 ➔ May 2026
Enrollment closed • Trial completion date • Trial primary completion date • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology
|